References
Eter N, Mohr A, Wachtlin J et al (2016) Dexamethasone intravitreal implant in retinal vein occlusion: real-life data from a prospective, multicenter clinical trial. Graefes Arch Clin Exp Ophthalmol. doi:10.1007/s00417-016-3431-x
Freund KB, Korobelnik JF, Deveny R et al (2015) Treat-and extend regimens with anti-VEGF agents in retinal diseases. Retina 35:1489–1506
Chan A, Duker JS, Ko TH, Fujimoto JG, Schuman JS (2006) Normal macular thickness measurements in healthy eyes using stratus optical coherence tomography. Arch Ophthalmol 124:193–198
Gover S, Murthy RK, Brar VS, Chalam KV (2009) Normative data formacular thickness by high-definition spectral-domain optical coherence tomography (Spectralis). Am J Ophthalmol 148:266–271
Kuppermann BD, Haller JA, Bandello F (2014) Onset and duration of visual acuity improvement after dexamethasone intravitreal implant in eyes with macular edema due to retinal vein occlusion. Retina 34:1743–1749
Coscas G, Augustin A, Bandello F et al (2014) Retreatment with ozurdex for macular edema secondary to retinal vein occlusion. Eur J Ophthalmol 24:1–9
Călugăru D, Călugăru M (2015) Intravitreal bevacizumab in acute central/hemicentral retinal vein occlusions: three-year results of a prospective clinical study. J Ocul Pharmacol Ther 31:78–86
Călugăru D, Călugăru M (2015) Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 Galileo study. Am J Ophthalmol 159:607–608
Călugăru D, Călugăru M (2016) Pro-permeability factors after dexamethasone implant in retinal vein occlusion: the Ozurdex for Retinal Vein Occlusion (ORVO) Study. Am J Ophthalmol 161:215–216
Acknowledgments
All authors have completed and submitted the ICMJE form for disclosure of potential conflicts of interest. No financial disclosures. Both authors (D.C and M.C) were involved in design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.
The authors have full control of the primary data, and they agree to allow Graefe’s Archive for Clinical and Experimental Ophthalmology to review their data if requested.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge, or beliefs) in the subject matter or materials discussed in this manuscript.
Rights and permissions
About this article
Cite this article
Călugăru, D., Călugăru, M. Dexamethasone intravitreal implant in retinal vein occlusion:real-life data from a prospective, multicenter clinical trial. Graefes Arch Clin Exp Ophthalmol 255, 427–428 (2017). https://doi.org/10.1007/s00417-016-3559-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00417-016-3559-8